K. Kuester(1,3), A. Kovar(2), B. Brockhaus(2), C. Kloft(1,3) Matuzumab – A Population Pharmacokinetic Model and its Evaluation
|
Soy D1, Clopés A2, Farré R3, Mangues MA3 Population Pharmacokinetic Modeling Of Busulfan In Patients Undergoing Autologous Stem Cell Transplantation (ASCT) For Multiple Myeloma
|
Yumi Fukushima (1), Jean-Eric Charoin (1), Michael Brewster (2), E. Niclas Jonsson (1) Population Pharmacokinetic Analysis of Trastuzumab (Herceptin®) based on Data from Three Different Dosing Regimens.
|
Dickinson GL (1), Dawson M (2), Ward TH (2), Danson S (3), Ranson M (2), Dive C (2), Aarons L (1). Population pharmacokinetics of a novel anticancer drug, RH1, in terminal cancer patients.
|
E.K. Hansson(1), M. Sandström(2), H. Lindman(3), L.E. Friberg(1) Modelling of Chemotherapy-induced Febrile Neutropenia using the Predicted Degree and Duration of Myelosuppression
|
J.E. Wallin, L. E. Friberg and M. O. Karlsson Predictive Performance of a Myelosuppression Model for Dose Individualization; Impact of Inter-Occasion Variability and Level and Type of Information Provided
|
I. Grabnar(1), B. Faganel(2), V. Dolzan(3), A. Mrhar(1), J. Jazbec(2) Population Pharmacokinetics of Methotrexate in Children with Lymphoid Malignancy
|
Ricardo Nalda-Molina1, Belén Valenzuela(1), Arturo Soto-Matos(2), Bernardo Miguel-Lillo(2), Miguel Angel Izquierdo(2) Population Pharmacokinetics of Aplidin® (plitidepsin) in Subjects with Cancer
|
Ramón-López A. (1), Nalda-Molina R. (1), Valenzuela B. (1), Pérez Ruixo J.J.(2) Semi-mechanistic PKPD model for neutropenia using K-PD model in patients receiving high dose of chemotherapy
|
Aldaz A. (1), Sayar O. (1), Zufia L.(1), Viudez A.(2), Rifon J.(3), Nieto Y.(4) Comparison between NONMEM and NPAG for gemcitabine modelling
|
Sayar O.(1), Aldaz A. (1),Zufia L.(1), Viudez A.(2), Rifón J.(3), Nieto Y.(4) New model for gemcitabine and its metabolites
|